Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1057 | 963 | 1207 | 1001 | 1487 | 1788 |
Fund Return | 5.73% | -3.74% | 20.74% | 0.02% | 8.25% | 5.98% |
Place in category | 511 | 730 | 480 | 225 | 142 | 152 |
% in Category | 52 | 74 | 47 | 41 | 28 | 54 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
JPI Global Income Fund C dist USD h | 17.93B | 10.31 | 3.12 | 4.85 | ||
JPI Global Income Fund C mth USD he | 17.93B | 10.32 | 3.13 | 4.85 | ||
JPI Global Income Fund D acc USD he | 17.93B | 9.47 | 2.09 | 3.81 | ||
JPI Global Income Fund D mth USD he | 17.93B | 9.44 | 2.05 | 3.79 | ||
Global Income Fund C div USD hedged | 17.93B | 10.33 | 3.13 | 4.87 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
LU2112291526 | 766.88M | 8.79 | 2.99 | - | ||
World Healthscience Fund C2u | 387.94M | 7.65 | 1.73 | 6.66 | ||
World Healthscience Fund D2u | 1.31B | 9.47 | 3.79 | 8.82 | ||
World Healthscience Fund X2 USD | 46.7M | 10.37 | 4.81 | 9.91 | ||
World Healthscience Fund A2 | 6.77B | 8.78 | 3.01 | 8.01 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Eli Lilly | US5324571083 | 8.85 | 748.01 | -0.25% | |
UnitedHealth | US91324P1021 | 7.98 | 590.87 | -1.11% | |
Novo Nordisk B | DK0062498333 | 5.92 | 750.9 | +4.03% | |
AbbVie | US00287Y1091 | 5.72 | 176.95 | +3.04% | |
Thermo Fisher Scientific | US8835561023 | 4.74 | 513.26 | -0.55% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Sell | Sell | Buy |
Technical Indicators | Strong Sell | Strong Sell | BUY |
Summary | Strong Sell | Strong Sell | Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review